Related Experiment Video
Updated: Aug 10, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis
1Division of Orthopedic Surgery, Scripps Clinic and Research Foundation, La Jolla, Calif.
Abstract:
Low molecular weight heparins are providing a new prophylactic option for preventing deep vein thrombosis (DVT) in patients undergoing joint replacement surgery. Fragmentation of heparin in laboratory studies revealed differences in coagulation and bleeding factors. This unexpected finding led to clinical trials, starting in 1985 in Europe and the United States. By late 1993, more than 10,000 patients had been admitted to clinical trials of low molecular weight heparins (LMWH) for prevention of DVT. Results of these trials indicated that LMWHs were more effective than unfractionated heparins or warfarin in preventing DVT with no significant increase in bleeding noted.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

